Abstract: Glaucoma is a type of eye disease caused by high intraocular pressure (IOP). An increase in IOP causes damage to the appearance and function of the optic nerve and, when left untreated, leads to vision loss. However, once inserted, the conventional aqueous humor drainage devices implanted to control IOP continuously discharge a certain amount of aqueous humor regardless of how high or low the IOP is and thus have difficulty in effectively controlling the IOP. The present disclosure, which has been devised to address the above problems, relates to a novel aqueous humor drainage device for controlling IOP. The aqueous humor drainage device of the present disclosure, which is a double-layer aqueous humor drainage device having a tube made of a shape memory polymer included therein, can control both low IOP and high IOP and thus has an excellent effect of maintaining IOP within a clinically acceptable range.

Abstract: A use method of agmatine or a pharmaceutically allowable salt thereof, and a pharmaceutical composition comprising the same are disclosed. The method and pharmaceutical composition of the present invention can effectively cure or prevent eye diseases preferably including glaucoma, retinopathy, and optic neuropathy associated with apoptosis in retinal ganglion cells (RGCs), particularly hypoxia-induced or tumor necrosis factor-? (TNF-?)-induced apoptosis.

Abstract: A use method of agmatine or a pharmaceutically allowable salt thereof, and a pharmaceutical composition comprising the same are disclosed. The method and pharmaceutical composition of the present invention can effectively cure or prevent eye diseases preferably including glaucoma, retinopathy, and optic neuropathy associated with apoptosis in retinal ganglion cells (RGCs), particularly hypoxia-induced or tumor necrosis factor-? (TNF-?)-induced apoptosis.